{"DataElement":{"publicId":"3190690","version":"1","preferredName":"Agent Post Registration Cimetidine Administered Month Duration","preferredDefinition":"the number of months between registration and administration Cimetidine, a histamine H(2)-receptor antagonist that enhances anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production, following officially enrolling on a clinical trial.","longName":"3190549v1.0:3190443v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3190549","version":"1","preferredName":"Agent Post Registration Cimetidine Administered","preferredDefinition":"information related to administration of Cimetidine, a histamine H(2)-receptor antagonist that enhances anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production, following officially enrolling on a clinical trial.","longName":"2177199v1.0:3190547v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177199","version":"1","preferredName":"Agent","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"Agent","context":"CCR","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAFB2021-86EC-28AE-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-04-10","endDate":null,"createdBy":"CCR_GENERIC","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":"Updated to add EVS Concept code - dw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3190547","version":"1","preferredName":"Post Registration Cimetidine Administered","preferredDefinition":"Post; occuring after.:The act of listing or recording officially; officially qualified or enrolled.:A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04):Given.","longName":"C38008:C25646:C374:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Registration","conceptCode":"C25646","definition":"The act of listing or recording officially; officially qualified or enrolled.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cimetidine","conceptCode":"C374","definition":"A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BE060EC-1856-83A7-E040-BB89AD437A6E","latestVersionIndicator":"Yes","beginDate":"2011-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-09","modifiedBy":"ONEDATA","dateModified":"2011-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BE060EC-1867-83A7-E040-BB89AD437A6E","latestVersionIndicator":"Yes","beginDate":"2011-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3190443","version":"1","preferredName":"Decimal Month Duration","preferredDefinition":"the number of months (999.9) during which an event occurred.","longName":"3190443v1.0","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":"1","format":"999.9","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2480485","version":"1","preferredName":"Month Duration","preferredDefinition":"One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks.:The period of time during which something continues.","longName":"C29846:C25330","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Month","conceptCode":"C29846","definition":"One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Duration","conceptCode":"C25330","definition":"The period of time during which something continues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12F992CB-8A0F-32F3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-05-04","modifiedBy":"ONEDATA","dateModified":"2006-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BDF1709-A28C-FC2F-E040-BB89AD4345C7","latestVersionIndicator":"Yes","beginDate":"2011-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-09","modifiedBy":"CAMPBELB","dateModified":"2011-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Time to start of Cimetidine U","type":"Preferred Question Text","description":"Time to start of Cimetidine Use","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BEF8968-2173-C415-E040-BB89AD434922","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-10","modifiedBy":"CAMPBELB","dateModified":"2011-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}